The global Drug Eluting Stent (DES) Market, valued at USD 2897.6 million in 2022, is poised for significant growth, with forecasts projecting a rise to USD 4795.51 million by 2030. This growth is expected to occur at a steady compound annual growth rate (CAGR) of 6.5% during the forecast period spanning from 2023 to 2030.

Drug eluting stents are medical devices used to treat coronary artery disease by restoring blood flow to the heart. These stents are coated with medications that are slowly released over time to prevent the re-narrowing of the arteries, known as restenosis, following angioplasty.

Get Sample PDF @ https://www.snsinsider.com/sample-request/3323 

Key Players

The major key players are Abbott Laboratories, Boston Scientific Corporation, Medtronic, Cordis Corporation (a Johnson & Johnson company), Terumo Corporation, Biosensors International Group, Ltd, Biotronik SE & Co. KG, St. Jude Medical, Inc. and others.

Key factors driving the growth of the Drug Eluting Stent Market include:

  1. Increasing Prevalence of Cardiovascular Diseases: The rising incidence of cardiovascular diseases, including coronary artery disease and myocardial infarction, particularly among aging populations and those with risk factors such as obesity and diabetes, is driving the demand for effective treatment options such as drug eluting stents.

  2. Technological Advancements in Stent Design and Coating: Ongoing advancements in stent design, materials, and drug coating technologies are leading to the development of next-generation drug eluting stents with improved biocompatibility, deliverability, and efficacy, driving market growth.

  3. Growing Adoption of Minimally Invasive Interventions: Increasing preference for minimally invasive percutaneous coronary interventions (PCI), such as angioplasty and stenting, over traditional open-heart surgery is fueling the demand for drug eluting stents as a less invasive and effective treatment option for coronary artery disease.

  4. Expanding Geriatric Population: The aging population, particularly in developed countries, is driving the prevalence of cardiovascular diseases, creating a substantial patient pool in need of coronary artery interventions, including drug eluting stent placement.

KEY SEGMENTS

By Type

  • Coronary Stenting

  • Peripheral Stenting

By Scaffold

  • Cobalt-Chromium

  • Platinum-Chromium

  • Nitinol

  • Others

By Drug

  • Sirolimus

  • Paclitaxel

  • Zotarolimus

  • Everolimus

  • Others

By End User

  • Hospitals

  • Specialty Clinics

The forecast period of 2023-2030 is expected to witness continued innovation in drug eluting stent technologies, including the development of biodegradable stents, bioresorbable polymers, and coatings with enhanced drug delivery properties, to further improve clinical outcomes and patient satisfaction.

Geographically, North America currently dominates the Drug Eluting Stent Market, attributed to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and favorable reimbursement policies. However, regions such as Europe, Asia Pacific, and Latin America are expected to witness significant growth opportunities during the forecast period, driven by increasing healthcare expenditure and rising awareness about coronary artery interventions.

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Akash Anand – Head of Business Development & Strategy

[email protected]

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

Website: https://www.snsinsider.com